Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Share-based Compensation (2022 - 2025)

TriSalus Life Sciences' Share-based Compensation history spans 4 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 29.46% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $9.1 million, up 67.82%, while the annual FY2025 figure was $9.1 million, 67.82% up from the prior year.
  • Share-based Compensation reached $2.2 million in Q4 2025 per TLSIW's latest filing, down from $3.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.4 million in Q3 2025 to a low of $68000.0 in Q2 2023.
  • Average Share-based Compensation over 4 years is $1.2 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: surged 1775.0% in 2024, then grew 29.46% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $117000.0 in 2022, then surged by 754.7% to $1.0 million in 2023, then skyrocketed by 69.7% to $1.7 million in 2024, then grew by 29.46% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Share-based Compensation are $2.2 million (Q4 2025), $3.4 million (Q3 2025), and $1.9 million (Q2 2025).